Tyra Biosciences (NASDAQ:TYRA) Reaches New 12-Month Low – Here’s What Happened

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $13.12 and last traded at $13.14, with a volume of 59641 shares trading hands. The stock had previously closed at $13.67.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TYRA. UBS Group began coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price for the company. Wedbush restated an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, January 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $30.50.

Tyra Biosciences Stock Performance

The company has a 50-day moving average of $15.11 and a 200-day moving average of $18.81.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 7,779 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $16.29, for a total value of $126,719.91. Following the transaction, the director now directly owns 447,857 shares of the company’s stock, valued at approximately $7,295,590.53. This represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 21,998 shares of company stock worth $344,818. 15.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tyra Biosciences

A number of large investors have recently bought and sold shares of the company. Janus Henderson Group PLC acquired a new stake in Tyra Biosciences during the 3rd quarter valued at approximately $24,994,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Tyra Biosciences during the third quarter worth $593,000. JPMorgan Chase & Co. lifted its position in Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after purchasing an additional 3,896 shares during the period. Barclays PLC boosted its holdings in Tyra Biosciences by 200.5% in the third quarter. Barclays PLC now owns 37,625 shares of the company’s stock valued at $884,000 after purchasing an additional 25,106 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Tyra Biosciences by 2.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock worth $4,085,000 after purchasing an additional 3,792 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.